Literature DB >> 3292251

Incidence of ras gene mutations in neuroblastoma.

K Ballas1, J Lyons, J W Janssen, C R Bartram.   

Abstract

Using a rapid dot-blot screening procedure based on DNA amplification and hybridization to synthetic oligonucleotide probes, we investigated 18 neuroblastomas in various clinical stages for the presence of ras mutations. In none of the samples was a mutation in the relevant codons 12, 13 or 61 of Ha-ras, Ki-ras or N-ras found. These data virtually exclude the participation of mutated ras genes in the genesis of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292251     DOI: 10.1007/bf00442704

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Prevalence of ras gene mutations in human colorectal cancers.

Authors:  J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

Review 2.  ras genes.

Authors:  M Barbacid
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

3.  Novel transforming sequences in human acute myelocytic leukemia cell lines.

Authors:  J W Janssen; A C Steenvoorden; M Losekoot; C R Bartram
Journal:  Oncogene       Date:  1987-05       Impact factor: 9.867

4.  Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line.

Authors:  K Shimizu; M Goldfarb; M Perucho; M Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

5.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

Authors:  R C Seeger; G M Brodeur; H Sather; A Dalton; S E Siegel; K Y Wong; D Hammond
Journal:  N Engl J Med       Date:  1985-10-31       Impact factor: 91.245

6.  Concurrent mutations in two different ras genes in acute myelocytic leukemias.

Authors:  J W Janssen; J Lyons; A C Steenvoorden; H Seliger; C R Bartram
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

7.  Human neuroblastomas and abnormalities of chromosomes 1 and 17.

Authors:  F Gilbert; M Feder; G Balaban; D Brangman; D K Lurie; R Podolsky; V Rinaldt; N Vinikoor; J Weisband
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

8.  Amplification and expression of the N-myc gene in neuroblastoma.

Authors:  C R Bartram; F Berthold
Journal:  Eur J Pediatr       Date:  1987-03       Impact factor: 3.183

9.  A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides.

Authors:  M Verlaan-de Vries; M E Bogaard; H van den Elst; J H van Boom; A J van der Eb; J L Bos
Journal:  Gene       Date:  1986       Impact factor: 3.688

10.  RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

Authors:  J W Janssen; A C Steenvoorden; J Lyons; B Anger; J U Böhlke; J L Bos; H Seliger; C R Bartram
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

  10 in total
  6 in total

1.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

Review 2.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

Review 3.  Biology of tumors of the peripheral nervous system.

Authors:  G M Brodeur; J F Moley
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

4.  Mutations in PIK3CA are infrequent in neuroblastoma.

Authors:  Vincent Dam; Brian T Morgan; Pavel Mazanek; Michael D Hogarty
Journal:  BMC Cancer       Date:  2006-07-05       Impact factor: 4.430

5.  NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced apoptosis.

Authors:  P Ruggeri; L Cappabianca; A R Farina; L Gneo; A R Mackay
Journal:  Cell Death Discov       Date:  2016-02-01

6.  TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma.

Authors:  Luciana Gneo; Pierdomenico Ruggeri; Lucia Cappabianca; Antonietta Rosella Farina; Natalia Di Ianni; Andrew Reay Mackay
Journal:  Oncotarget       Date:  2016-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.